Decreased Susceptibility of the Cytochrome P450 2B6 Variant K262R to Inhibition by Several Clinically Important Drugs
Authors:
- Jyothi C. TalakadJTJyothi C. Talakad
- Santosh KumarSantosh Kumar
- James R. HalpertJHJames R. Halpert
- 1 March 2009
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 37 (3) , 644-650
Abstract
Cytochrome P450 (P450) 2B6 metabolizes a number of clinically relevant drugs and is one of the most highly polymorphic human P450 enzymes, with the Lys262→Arg substitution being especially common in several genetic variants. Therefore, K262R (2B6*4) was created in the CYP2B6dH background (N-terminal-modified and C-terminal His-tagged) and expressed in Escherichia coli. The recombinant CYP2B6dH and K262R were purified and studied to investigate the effect of the Lys262→Arg substitution with six of the most potent drug inhibitors of CYP2B6, namely, clopidogrel, clotrimazole, itraconazole, raloxifene, sertraline, and ticlopidine. K262R showed a >3-fold increase in the Ki values with clopidogrel, itraconazole, and raloxifene and ∼6-fold increase in Ki with sertraline compared with CYP2B6dH. Likewise, K262R showed 2-, 4-, and >20-fold higher Ks values than CYP2B6dH with clopidogrel, sertraline, and itraconazole, respectively. In contrast, when tested with several known type II inhibitors of CYP2B enzymes, K262R showed a 10-fold lower IC50 with 4-(phenyl)pyridine and ∼2-fold lower IC50 with 4-(4-nitrobenzyl)pyridine or 1-(4-phenyl)benzylimidazole than CYP2B6dH. Subsequent analysis predicted possible in vivo drug-drug interactions between the CYP2B6 substrate efavirenz and drug inhibitors clopidogrel, clotrimazole, itraconazole, sertraline, and ticlopidine. Furthermore, Q172H/K262R (2B6*6), which is the most common genetic variant of CYP2B6 harboring K262R, was created in CYP2B6dH, expressed, purified, and characterized for inhibition. Q172H/K262R showed a >6-fold increase in Ki with sertraline and clopidogrel compared with CYP2B6dH. The results suggest that individuals, especially homozygotes, with the 2B6*4 or 2B6*6 allele might be less susceptible to drug interactions resulting from P450 inhibition.Keywords
This publication has 27 references indexed in Scilit:
- Identification and Analysis of Conserved Sequence Motifs in Cytochrome P450 Family 2Journal of Biological Chemistry, 2008
- A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6Drug Metabolism and Disposition, 2007
- Rational Engineering of Human Cytochrome P450 2B6 for Enhanced Expression and Stability: Importance of a Leu264→Phe SubstitutionMolecular Pharmacology, 2007
- Drug-Drug Interaction between Itraconazole and Efavirenz in a Patient with AIDS and Disseminated HistoplasmosisClinical Infectious Diseases, 2007
- New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three‐dimensional quantitative structure‐activity relationship (3D‐QSAR) analysisBritish Journal of Pharmacology, 2007
- Surface Plasmon Resonance Analysis of Antifungal Azoles Binding to CYP3A4 with Kinetic Resolution of Multiple Binding OrientationsBiochemistry, 2006
- THE NATURALLY OCCURRING CYTOCHROME P450 (P450) 2B6 K262R MUTANT OF P450 2B6 EXHIBITS ALTERATIONS IN SUBSTRATE METABOLISM AND INACTIVATIONDrug Metabolism and Disposition, 2005
- Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null AllelesThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Substrates of Human Cytochromes P4S0 from Families CYP1 and CYP2: Analysis of Enzyme Selectivity and MetabolismDrug Metabolism and Drug Interactions, 2004
- Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6Pharmacogenetics, 2003